Avidity to raise $400M; Sato pays Arcutis $25M upfront to license topical roflumilast in Japan. Plus, news about Xencor, Otsuka, Typewriter Therapeutics, Cassava Sciences, Enveric Biosciences, Viking Therapeutics and Janux Therapeutics.
Avidity to raise $400M; Sato pays Arcutis $25M upfront to license topical roflumilast in Japan. Plus, news about Xencor, Otsuka, Typewriter Therapeutics, Cassava Sciences, Enveric Biosciences, Viking Therapeutics and Janux Therapeutics.
Enveric Biosciences is a development stage company that markets no products at this time. The content of this site is not intended to be promotional or to suggest any product or use of a product that has been approved by any regulatory body.
